Published in Int J Mol Sci on March 11, 2009
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol (2011) 1.57
A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron (2009) 1.48
HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol Dis (2010) 1.32
Increased CDK5 expression in HIV encephalitis contributes to neurodegeneration via tau phosphorylation and is reversed with Roscovitine. Am J Pathol (2011) 1.15
Autophagy in dementias. Brain Pathol (2012) 0.95
Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments. Pharmacol Ther (2013) 0.94
Role of HIV in amyloid metabolism. J Neuroimmune Pharmacol (2014) 0.90
Inhibition of cyclin-dependent kinase 5 but not of glycogen synthase kinase 3-β prevents neurite retraction and tau hyperphosphorylation caused by secretable products of human T-cell leukemia virus type I-infected lymphocytes. J Neurosci Res (2011) 0.88
Neuronal toxicity in HIV CNS disease. Future Virol (2012) 0.85
Role of neurotrophic factor alterations in the neurodegenerative process in HIV associated neurocognitive disorders. J Neuroimmune Pharmacol (2014) 0.84
Effects of HIV and combination antiretroviral therapy on cortico-striatal functional connectivity. AIDS (2015) 0.83
Morphine enhances HIV-1SF162-mediated neuron death and delays recovery of injured neurites. PLoS One (2014) 0.80
Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders. Curr HIV Res (2015) 0.79
PACAP27 is protective against tat-induced neurotoxicity. J Mol Neurosci (2014) 0.78
Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders. Br J Pharmacol (2014) 0.78
GSK3β-activation is a point of convergence for HIV-1 and opiate-mediated interactive neurotoxicity. Mol Cell Neurosci (2015) 0.77
Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity. J Neuroinflammation (2016) 0.77
Fibroblast growth factors 1 and 2 in cerebrospinal fluid are associated with HIV disease, methamphetamine use, and neurocognitive functioning. HIV AIDS (Auckl) (2016) 0.76
Impact of lithium alone and in combination with antidepressants on cytokine production in vitro. J Neural Transm (Vienna) (2014) 0.76
The role of tau protein in HIV-associated neurocognitive disorders. Mol Neurodegener (2014) 0.76
Effects of Morphine on Behavioral Task Performance in SIV-Infected Rhesus Macaques. J Neuroimmune Pharmacol (2016) 0.75
New tools for the investigations of Neuro-AIDS at a molecular level: The potential role of data-mining. Bioinformation (2013) 0.75
Challenging New Targets for CNS-HIV Infection. Front Neurol (2012) 0.75
Chronic SIV and morphine treatment increases heat shock protein 5 expression at the synapse. J Neurovirol (2015) 0.75
The EGF epidermal growth factor counteracts Tat modulation of human endogenous retroviruses of the W family in astrocytes. J Neurovirol (2017) 0.75
CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev (1999) 24.83
Wnt signalling regulates adult hippocampal neurogenesis. Nature (2005) 6.66
The neuropathogenesis of AIDS. Nat Rev Immunol (2005) 6.54
Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature (2001) 5.60
Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature (1999) 5.53
The HNRC 500--neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc (1995) 5.38
A decade of CDK5. Nat Rev Mol Cell Biol (2001) 5.24
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev (2005) 4.65
Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature (2000) 4.31
HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol (2002) 4.20
Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol (1995) 3.78
Potential role for adult neurogenesis in the encoding of time in new memories. Nat Neurosci (2006) 3.78
Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol (1997) 3.38
Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci U S A (1998) 3.18
Multipotent progenitor cells in the adult dentate gyrus. J Neurobiol (1998) 3.15
Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol (2005) 3.02
Enriched environment and physical activity stimulate hippocampal but not olfactory bulb neurogenesis. Eur J Neurosci (2003) 2.93
Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol (2003) 2.93
Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol (1997) 2.92
Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science (1990) 2.87
Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron (2005) 2.68
HIV-1 promotes quiescence in human neural progenitor cells. J Infect Dis (2004) 2.53
The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci (2002) 2.53
Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology (2002) 2.47
Environmental enrichment and voluntary exercise massively increase neurogenesis in the adult hippocampus via dissociable pathways. Hippocampus (2006) 2.43
Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci U S A (1999) 2.40
Serine 732 phosphorylation of FAK by Cdk5 is important for microtubule organization, nuclear movement, and neuronal migration. Cell (2003) 2.20
Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis (2002) 2.19
AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations. Ann Neurol (1995) 2.14
Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS (2006) 2.13
Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc Natl Acad Sci U S A (2005) 2.10
New neurons in the dentate gyrus are involved in the expression of enhanced long-term memory following environmental enrichment. Eur J Neurosci (2005) 2.03
Fibroblast growth factors and their receptors in the central nervous system. Cell Tissue Res (2003) 1.94
Cdk5 regulates accurate maturation of newborn granule cells in the adult hippocampus. PLoS Biol (2008) 1.92
p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J Neurosci (2001) 1.87
The neuropathogenesis of HIV-1 infection. J Leukoc Biol (1994) 1.83
Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS (2002) 1.78
Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann Neurol (2000) 1.75
The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells. Biochem J (1994) 1.75
Human immunodeficiency virus-infected macrophages produce soluble factors that cause histological and neurochemical alterations in cultured human brains. J Clin Invest (1991) 1.71
HIV-1 Tat through phosphorylation of NMDA receptors potentiates glutamate excitotoxicity. J Neurochem (2001) 1.64
Chemokines and receptors in HIV encephalitis. AIDS (1998) 1.59
Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry (2000) 1.56
HIV-1-associated dementia: a basic science and clinical perspective. AIDS Read (2002) 1.54
HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. J Neurochem (1999) 1.53
Human immunodeficiency virus encephalitis is the pathological correlate of dementia in acquired immunodeficiency syndrome. Ann Neurol (1994) 1.52
The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol (2003) 1.51
Cyclin-dependent kinase 5 is essential for neuronal cell cycle arrest and differentiation. J Neurosci (2005) 1.50
Cyclin-dependent kinase 5 mediates neurotoxin-induced degradation of the transcription factor myocyte enhancer factor 2. J Neurosci (2005) 1.40
Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway. Implications for neuroprotection. J Biol Chem (2002) 1.39
Effects of human immunodeficiency virus type 1 on astrocyte gene expression and function: potential role in neuropathogenesis. J Neurovirol (2004) 1.38
The shifting patterns of HIV encephalitis neuropathology. Neurotox Res (2005) 1.36
Calcium dysregulation and neuronal apoptosis by the HIV-1 proteins Tat and gp120. J Acquir Immune Defic Syndr (2002) 1.35
Cdk5 is essential for adult hippocampal neurogenesis. Proc Natl Acad Sci U S A (2008) 1.34
The neuropathogenesis of the AIDS dementia complex. AIDS (1997) 1.34
An update on the neuropathology of HIV in the HAART era. Histopathology (2004) 1.31
Cdk5 promotes synaptogenesis by regulating the subcellular distribution of the MAGUK family member CASK. Neuron (2007) 1.30
Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants. Neurology (2003) 1.29
Patterns of gene dysregulation in the frontal cortex of patients with HIV encephalitis. J Neuroimmunol (2004) 1.29
Activation of cell-cycle-associated proteins in neuronal death: a mandatory or dispensable path? Trends Neurosci (2001) 1.29
Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci (2003) 1.28
Synaptic activity becomes excitotoxic in neurons exposed to elevated levels of platelet-activating factor. J Clin Invest (2005) 1.25
Human immunodeficiency virus type 1 infection of human brain-derived progenitor cells. J Virol (2004) 1.24
The activation of glycogen synthase by insulin switches from kinase inhibition to phosphatase activation during adipogenesis in 3T3-L1 cells. J Biol Chem (1998) 1.22
Cdk5 on the brain. Cell Growth Differ (2001) 1.21
Lithium ameliorates HIV-gp120-mediated neurotoxicity. Mol Cell Neurosci (2002) 1.20
Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J Neurochem (2002) 1.19
Evidence for the participation of the neuron-specific CDK5 activator P35 during laminin-enhanced axonal growth. J Neurosci (1998) 1.18
Pathobiology of human immunodeficiency virus dementia. Semin Neurol (1999) 1.17
Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology (2006) 1.16
Activation of cyclin-dependent kinase 5 by calpains contributes to human immunodeficiency virus-induced neurotoxicity. J Neurochem (2007) 1.16
Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J Neurosci (2005) 1.16
Lithium improves HIV-associated neurocognitive impairment. AIDS (2006) 1.16
The neurology of HIV infection. J Neurol Neurosurg Psychiatry (2004) 1.15
Cyclin-dependent kinases as cellular targets for antiviral drugs. J Antimicrob Chemother (2002) 1.15
Cyclin-dependent kinase-5 in neurodegeneration. J Neurochem (2004) 1.14
Human immunodeficiency virus type 1 and its coat protein gp120 induce apoptosis and activate JNK and ERK mitogen-activated protein kinases in human neurons. Ann Neurol (1997) 1.11
Human immunodeficiency virus-1/surface glycoprotein 120 induces apoptosis through RNA-activated protein kinase signaling in neurons. J Neurosci (2007) 1.11
HIV-1 and the brain: connections between HIV-1-associated dementia, neuropathology and neuroimmunology. Microbes Infect (2002) 1.10
Regulation of cyclin-dependent kinase 5 catalytic activity by phosphorylation. Proc Natl Acad Sci U S A (1999) 1.07
Activation of glycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. Eur J Neurosci (2001) 1.06
The cell cycle as a therapeutic target for Alzheimer's disease. Pharmacol Ther (2005) 1.06
Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase-3beta to antagonize nuclear factor-kappaB survival pathway in neurons. Eur J Neurosci (2006) 1.05
HIV-infection of the central nervous system: the tightrope walk of innate immunity. Mol Immunol (2005) 1.04
Crosstalk between components of the blood brain barrier and cells of the CNS in microglial activation in AIDS. Brain Pathol (2001) 1.02
The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator. Neurosignals (2003) 1.02
Fibroblast growth factor modulates HIV coreceptor CXCR4 expression by neural cells. HNRC Group. J Neurosci Res (2000) 1.00
Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS. J Neuroimmune Pharmacol (2006) 1.00
Oxidative stress, perturbed calcium homeostasis, and immune dysfunction in Alzheimer's disease. J Neurovirol (2002) 0.99
Signalling crosstalk in FGF2-mediated protection of endothelial cells from HIV-gp120. BMC Neurosci (2005) 0.96
Chemokine receptor utilization and macrophage signaling by human immunodeficiency virus type 1 gp120: Implications for neuropathogenesis. J Neurovirol (2004) 0.95
Chemokine receptors in the brain: their role in HIV infection and pathogenesis. AIDS (2002) 0.94
Investigation of HIV-infected macrophage neurotoxin production from patients with AIDS dementia. Adv Neuroimmunol (1994) 0.93
Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders. Int Rev Psychiatry (2008) 0.93
Differential vulnerability of calbindin-immunoreactive neurons in HIV encephalitis. J Neuropathol Exp Neurol (1995) 0.93
Brain-derived neurotrophic factor-induced phosphorylation of neurofilament-H subunit in primary cultures of embryo rat cortical neurons. J Cell Sci (2000) 0.93
Activation of endothelial cell mitogen activated protein kinase ERK(1/2) by extracellular HIV-1 Tat protein. Endothelium (2001) 0.92
Amelioration of neurotoxic effects of HIV envelope protein gp120 by fibroblast growth factor: a strategy for neuroprotection. J Neuropathol Exp Neurol (2001) 0.91
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A (2009) 6.87
alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol (2002) 6.64
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science (2005) 5.52
Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science (2005) 5.49
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature (2006) 4.54
In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A (2011) 4.38
Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med (2009) 4.11
The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest (2008) 4.09
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci (2007) 3.73
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell (2011) 3.28
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell (2012) 3.16
Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron (2010) 3.15
Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res (2002) 2.96
Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat Med (2011) 2.87
Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell (2009) 2.87
Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci U S A (2003) 2.83
Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J Neurosci (2009) 2.82
The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci (2013) 2.78
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A (2002) 2.76
Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci (2005) 2.75
Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem (2010) 2.67
Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci (2004) 2.64
Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem (2004) 2.62
Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci U S A (2004) 2.55
Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J Neurosci (2011) 2.53
Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol (2004) 2.37
Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci (2005) 2.34
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex (2002) 2.31
α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem (2012) 2.31
Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry (2010) 2.30
Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol (2010) 2.29
Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc Natl Acad Sci U S A (2005) 2.29
Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci (2003) 2.28
Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A (2003) 2.24
Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat Chem Biol (2011) 2.24
Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol (2010) 2.20
Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One (2011) 2.19
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS (2006) 2.13
Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron (2010) 2.10
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med (2012) 2.07
Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS (2005) 2.07
Neuropathologic confirmation of definitional criteria for human immunodeficiency virus-associated neurocognitive disorders. J Neurovirol (2007) 2.03
Loss of TGF-beta 1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron (2003) 2.02
Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science (2004) 2.00
Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem (2011) 1.96
Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. J Comp Neurol (2004) 1.92
Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One (2010) 1.92
Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res (2006) 1.91
Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet (2010) 1.90
Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology (2013) 1.88
Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J Clin Invest (2006) 1.87
Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci (2005) 1.85
Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One (2008) 1.84
Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol (2010) 1.81
A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci (2010) 1.80
Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS (2002) 1.78
Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS. J Clin Invest (2005) 1.78
Increased BMP6 levels in the brains of Alzheimer's disease patients and APP transgenic mice are accompanied by impaired neurogenesis. J Neurosci (2010) 1.78
Increased proteasome activity in human embryonic stem cells is regulated by PSMD11. Nature (2012) 1.75
A mouse forward genetics screen identifies LISTERIN as an E3 ubiquitin ligase involved in neurodegeneration. Proc Natl Acad Sci U S A (2009) 1.74
Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol (2006) 1.73
Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A (2013) 1.73
Polyamine pathway contributes to the pathogenesis of Parkinson disease. Proc Natl Acad Sci U S A (2010) 1.73
Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J Neurosci (2006) 1.69
Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. Arch Neurol (2004) 1.65
Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci U S A (2008) 1.64
Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis (2007) 1.63
Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci (2005) 1.63
Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci (2012) 1.63
Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription. Cell (2013) 1.61
Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci (2002) 1.58
Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem (2009) 1.57
Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks. J Comp Neurol (2009) 1.57
Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J Neurosci (2002) 1.56
Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol (2009) 1.55
Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun (2013) 1.55